Solasia Pharma K.K. revised consolidated financial guidance for the fiscal year ending December 31, 2022. For the year, the company expects revenue of ¥1,150 million, operating loss of ¥2,150 million, loss attributable to owners of parent of ¥2,250 and basic loss per share of ¥13.41 compared to previous guidance of revenue in the range of ¥2,300 million to ¥3,800 million, operating loss in the range of ¥1,100 million to operating profit of ¥150 million, loss in the range of ¥1,200 million to profit of ¥50 million, basic loss per share in the range of ¥8.99 to basic earnings per share of ¥0.37.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
25 JPY | -3.85% | 0.00% | -44.44% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-44.44% | 30.53M | |
-2.86% | 87.31B | |
+2.63% | 40.86B | |
-23.10% | 29.36B | |
+58.56% | 24.49B | |
-15.65% | 17.31B | |
-19.21% | 11.62B | |
-15.61% | 11.31B | |
-44.02% | 11.26B | |
+5.17% | 8.31B |
- Stock Market
- Equities
- 4597 Stock
- News Solasia Pharma K.K.
- Solasia Pharma K.K. Revises Consolidated Financial Guidance for the Fiscal Year Ending December 31, 2022